OCUL
OCULAR THERAPEUTIX, INC
NASDAQ · Healthcare · Biotechnology · US
$6.40
+1.82%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$6.30
From 52W high−60.25%
Volume122310.00
Market cap$1.41B
P/E (TTM)—
P/S (TTM)27.0x
Div yield—
Key dataOct 20, 2026
Open
$6.30
From 52W high
−60.25%
Volume
122310.00
Market cap
$1.41B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.1x
P/E (TTM)
—
RSI (14)
26.1
MomentumView details →
1D Return
+1.82%
YTD Return
−48.78%
SummaryUpdated Jun 1, 2026
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company founded in 2006 and headquartered in Bedford, Massachusetts. The company specializes in developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel-based formulation technology. Since going public in 2014, Ocular Therapeutix has evolved from a clinical-stage company into a commercial organization with marketed products and a robust pipeline of sustained-release drug delivery systems for various ocular conditions.
Similar companies
Latest newsMore news →
Sanjay Nayak resigned as Chief Strategy Officer of OCULAR THERAPEUTIX, INC4d agoOcular Therapeutix completed a positive Pre-NDA meeting with the U.S. FDA for its investigational wet AMD candidate AXPAXLI, confirming plans for a 4Q 2026 NDA submission.35d agoOcular Therapeutix announced that the FDA is aligned on its plan to submit a new drug application for Axpaxli injection for wet age-related macular degeneration.125d ago